Cytokinetics Gains 20.5% YTD: Buy, Sell or Hold the Stock?
Cytokinetics (CYTK) has seen a 20.5% year-to-date gain following the FDA approval of its drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM). The drug is experiencing strong commercial adoption in the U.S. and has launched in Europe, with further market expansion anticipated. While the company has a strong financial position and other pipeline candidates, its heavy reliance on Myqorzo and competition from Bristol Myers Squibb's Camzyos suggest a "Hold" rating for existing shareholders, with new investors advised to await a more attractive entry point.
Cytokinetics EVP research & development sells $265,370 in stock By Investing.com
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., sold 3,500 shares of common stock for $265,370 on August 18, 2026, after acquiring them through non-qualified stock options. This sale follows the company's strong second-quarter financial results, driven by the success of its heart drug MYQORZO, and positive revisions to analyst estimates, despite the stock appearing overvalued by some metrics.
Cytokinetics (CYTK) EVP Research & Development Fady Malik Sells 3,500 Shares
Fady Malik, EVP of Research & Development at Cytokinetics (CYTK), sold 3,500 shares for $265,370 on August 18, 2026, adding to a consistent pattern of insider selling over the past year. Despite the stock trading at a significant discount to its GuruFocus intrinsic value estimate, the overwhelming imbalance of 78 insider sells versus zero buys suggests caution for investors. The "Possible Value Trap" designation and mixed institutional investor activity further advise prudence, indicating potential underlying concerns despite the apparent undervaluation.
Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells $265,370.00 in Stock
Cytokinetics (NASDAQ:CYTK) EVP Fady Ibraham Malik sold 3,500 shares of the company's stock for $265,370 on August 18th, under a pre-arranged trading plan. This transaction reduced his direct ownership to 153,902 shares. The stock traded near $76.08, with analysts maintaining a "Moderate Buy" consensus and an average price target of $102.20.
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cytokinetics announced inducement grants of stock options and restricted stock units (RSUs) to 12 new employees in August 2026. These grants, totaling 27,565 shares of common stock options and 18,273 RSUs, were made as a material inducement for their employment under Nasdaq Listing Rule 5635(c)(4). The awards have specific vesting schedules and exercise prices, designed to align employee interests with the company's long-term success.
Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative
Cytokinetics (CYTK) reported weaker Q2 2026 financial results with reduced revenue and a wider net loss, but highlighted strong commercial traction for MYQORZO and progress in its cardiology pipeline. Investors are now focused on MYQORZO's global rollout, particularly in Europe, and how this growth will offset current losses and high R&D spending, as well as manage cash burn, which is seen as a key risk. Despite varying analyst forecasts, the article suggests that MYQORZO's momentum could be crucial in establishing a sustainable revenue base for the company.
Cytokinetics (NASDAQ:CYTK) Raised to Hold at Wall Street Zen
Wall Street Zen upgraded Cytokinetics (NASDAQ:CYTK) from "Sell" to "Hold" on Sunday, despite the broader analyst consensus remaining a "Moderate Buy." The company exceeded quarterly expectations with an adjusted loss of $1.50 per share and revenue of $28.62 million. While company insiders sold shares, institutional investors, including Millennium Management, increased their holdings.
Will MYQORZO Traction Amid Weaker Q2 2026 Results Change Cytokinetics' (CYTK) Narrative
Cytokinetics reported weaker Q2 2026 financial results with lower revenue and a wider net loss, but highlighted significant commercial traction for its drug MYQORZO and progress in its cardiology portfolio. This traction, including European market authorizations, is seen as crucial for the company's long-term potential despite current losses and high R&D spend. Investors are focusing on MYQORZO's uptake and upcoming regulatory milestones, with analyst forecasts for 2029 suggesting a substantial revenue increase and potential stock upside.
Capricor shares spike on CEO comments; Cytokinetics sues Bristol Myers
Capricor Therapeutics shares jumped over 60% after its CEO indicated the FDA is open to reviewing an updated Duchenne muscular dystrophy cell therapy submission. Separately, Cytokinetics is suing Bristol Myers Squibb to protect patents for its heart drug Myqorzo, accusing BMS of attempting to hinder its market success. Other biotech updates include Valneva's Lyme disease vaccine application acceptance in Europe, InduPro's successful Series B funding round for cancer drugs, Zealand Pharma selling drug rights for $100 million, and Rigel Pharmaceuticals launching its new breast cancer drug Veppanu.
Wellington group discloses over 5% Cytokinetics (CYTK) holding for clients
Wellington Management Group LLP and related entities have disclosed a 5.12% beneficial ownership stake in Cytokinetics, Incorporated (CYTK) for their clients, as detailed in an Amendment No. 2 to a Schedule 13G filing. This holding, totaling 7,116,724 shares, is managed by various Wellington investment advisers, with no single client holding more than five percent. The filing indicates shared voting power over 6,231,890 shares and shared dispositive power over all 7,116,724 shares.
CYTK Maintained by Barclays -- Price Target Raised to $110
Barclays has maintained an Overweight rating for Cytokinetics (CYTK) and increased its price target to $110, reflecting a positive outlook despite the company being unprofitable. The stock is considered undervalued by 60.9% according to GF Value™, but its GF Score™ of 51/100 indicates average overall performance with strong growth potential but weak profitability. Insider activity shows more selling than buying, suggesting caution for investors.
Cytokinetics files lawsuit seeking patent judgment against Bristol-Myers Squibb
Cytokinetics has filed a lawsuit against Bristol-Myers Squibb and MyoKardia, seeking a declaratory judgment that it does not infringe on U.S. Patent No. 12,616,697 and that the patent's claims are invalid. The company also seeks an injunction to prevent infringement litigation related to its product MYQORZO. This legal action comes as Cytokinetics reported strong Q2 2026 financial results, exceeding expectations due to robust sales of MYQORZO.
Form 8K Cytokinetics Inc For: 13 August By Investing.com
This article from Investing.com reports that Cytokinetics Inc. filed a Form 8K on August 13th. The Form 8K is a crucial document that companies file with the SEC to announce major events that shareholders should know about. No specific details about the content of the 8K filing are provided within this brief announcement.
Barclays raises Cytokinetics stock price target on strong Myqorzo sales
Barclays has increased its price target for Cytokinetics (NASDAQ: CYTK) shares to $110 from $95, maintaining an Overweight rating. This upgrade follows strong second-quarter Myqorzo sales of $25.3 million, significantly beating consensus estimates. The drug's successful launch and prescription growth, alongside the company's better-than-expected Q2 financial results, have contributed to a positive outlook from analysts.
Handelsbanken Fonder AB Grows Stock Holdings in Cytokinetics, Incorporated $CYTK
Handelsbanken Fonder AB increased its stake in Cytokinetics, Incorporated by 63.8% in the second quarter, now owning 405,000 shares worth $34.5 million. This comes as other institutional investors have also adjusted their positions in the biopharmaceutical company. Analysts have largely maintained a "Moderate Buy" rating for Cytokinetics, with several price target increases, while recent insider stock sales were noted to be part of pre-arranged trading plans.
Cytokinetics Inc (CYTK) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Cytokinetics Inc (CYTK), detailing its current earnings forecast score, average price target, and analyst ratings. Based on 22 analysts, the stock has a strong buy recommendation with an average target price of $79.00 and an upside space of +41.07%. It also includes FAQs about expected revenue, price targets, and past EPS performance.
Dimensional Fund Advisors LP Has $6.23 Million Stock Holdings in Cytokinetics, Incorporated $CYTK
Dimensional Fund Advisors LP significantly increased its stake in Cytokinetics, Incorporated, acquiring an additional 75.2% of shares, totaling 94,503 shares valued at $6.23 million. Other institutional investors also raised their positions, reflecting broadly positive sentiment despite recent insider selling and a year-over-year revenue decline. Analysts maintain a "Moderate Buy" rating with an average price target of $101.15, well above the current stock price.
Cytokinetics president & CEO Robert Blum sells $575,700 in shares
Cytokinetics President and CEO Robert Blum sold 7,500 shares of common stock for $575,700 and simultaneously acquired 7,500 shares through stock options for $79,500. Following these transactions, Blum holds 377,820 direct shares and additional indirect shares. The company's stock has seen a 133% return over the past year, and it recently surpassed Q2 2026 financial expectations, partly due to the successful launch of its heart drug, MYQORZO.
Cytokinetics president & CEO Robert Blum sells $575,700 in shares
Robert I. Blum, President and CEO of Cytokinetics Inc. (NASDAQ:CYTK), sold 7,500 shares of common stock for $575,700, while also acquiring 7,500 shares through option exercise for $79,500. Following these transactions, Blum directly holds 377,820 shares, with additional indirect holdings. This comes as CYTOKINETICS stock has seen a 133% return over the past year and recently reported better-than-expected Q2 2026 financial results driven by its drug MYQORZO.
Insider Selling: Cytokinetics (NASDAQ:CYTK) CEO Sells $575,700.00 in Stock
Cytokinetics CEO Robert Blum sold 7,500 shares of the company's stock for $575,700, reducing his direct holdings by 1.95%. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Despite the insider selling, analysts generally maintain a "Moderate Buy" rating for CYTK with an average price target of $101.15, following the company's better-than-expected quarterly revenue and earnings.
Cytokinetics, Incorporated Revenue Breakdown – NASDAQ:CYTK
Cytokinetics, Incorporated (NASDAQ: CYTK) generated $88.04 million USD in revenue last year, primarily from its Muscle Activators and Muscle Inhibitors segment. This represents a significant increase from the previous year's $18.47 million USD. The United States was the greatest contributor to this revenue.
CYTOKINETICS, INCORPORATED : LEERINK PARTNERS RAISES TARGET PRICE TO $103 FROM $100
LEERINK PARTNERS has increased its target price for CYTOKINETICS, INCORPORATED (CYTK.O) from $100 to $103. The article is a brief financial news update from Reuters, indicating a positive analyst sentiment towards the company. It notes that the content reflects only the author's opinion and is not investment advice.
Cytokinetics, Incorporated (CYTK) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Cytokinetics, Incorporated (NASDAQ:CYTK) on behalf of investors who purchased securities before December 27, 2023. The investigation seeks to determine if the company or its officers engaged in corporate wrongdoing. The law firm is encouraging affected stockholders to contact them for more information and to assist with the investigation, noting that they operate on a contingency fee basis.
Cytokinetics (CYTK) Stock Looks Near Fair Value Despite UK MYQORZO Approval
Cytokinetics (CYTK) stock has shown strong returns over five years, but its current valuation suggests it's neither a clear bargain nor obviously overvalued. Despite recent UK approval for MYQORZO, the stock's high price-to-book ratio is not a reliable indicator due to the company's development-heavy phase. Future performance will largely depend on the successful execution of approvals, launches, and funding for its pipeline.
Wall Street Zen Downgrades Cytokinetics (NASDAQ:CYTK) to Sell
Wall Street Zen downgraded Cytokinetics (NASDAQ:CYTK) to a "sell" rating from "hold," despite the broader analyst consensus remaining a "Moderate Buy." This downgrade follows the biopharmaceutical company's quarterly results, which saw revenue decline 57.1% year-over-year and substantial losses, although reported revenue and EPS still beat analyst expectations. Shares opened lower, and executives have engaged in significant insider selling over the past 90 days.
Citizens raises Cytokinetics stock price target on strong launch
Citizens has raised its price target for Cytokinetics (NASDAQ:CYTK) to $110 from $105, maintaining a Market Outperform rating, citing the strong launch of MYQORZO and ongoing pipeline development. The company's stock has surged 131% over the past year, currently trading at $81.37, and its second-quarter 2026 financial results exceeded expectations with product sales of approximately $25 million. Despite a Strong Buy consensus among analysts and a projected 29% upside potential, InvestingPro suggests the stock might be overvalued, and analysts do not foresee profitability this year.
Cytokinetics (CYTK) Stock Sees MYQORZO Momentum Collide With Mounting Losses
Cytokinetics (CYTK) saw its shares fall 6% despite early success with its new cardiomyopathy drug, MYQORZO, which generated $25.3 million in net product revenue. The company posted a significant net loss of $198.8 million in Q2 2026, widening from the previous year, as heavy investments outpace current sales. While the MYQORZO launch shows promise and clinical milestones are being met, the substantial cash burn and recent shareholder dilution remain key concerns for investors.
Cytokinetics (NASDAQ:CYTK) Shares Down 6.6% - Here's What Happened
Cytokinetics (NASDAQ:CYTK) shares fell 6.6% despite reporting Q2 2026 revenues and EPS that beat analyst expectations. The stock decline was influenced by a significant year-over-year revenue decrease, widening losses, substantial operating cash outflow, and ongoing insider selling. Despite these concerns, Wall Street analysts maintain a "Moderate Buy" rating with an average price target of $100.85, and the company maintains a strong cash position.
Cytokinetics, Incorporated Stock 12‑Month Price Target Cut to $107.65, Implies 32% Upside
Cytokinetics, Incorporated's average 12-month stock price target has been slightly cut from $108.47 to $107.65 by 20 analysts, still implying a 32% potential upside from its August 6 closing price. The consensus rating remains a "Buy" across 23 covering analysts, with 21 buys and 2 holds.
CYTOKINETICS INC Q2 2026: Revenue $28.6M, EPS $(1.50) — 10-Q Summary
CYTOKINETICS INC (CYTK) reported Q2 2026 results with revenue of $28.6 million, primarily driven by the first commercial sales of MYQORZO, which generated $25.3 million. The company posted a net loss of $198.8 million and diluted EPS of $(1.50), both wider than the previous year. Key business highlights include global approvals and commercial launches of MYQORZO, expansion of salesforce, and continued pipeline progress for other drug candidates.
Needham & Company LLC Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock
Needham & Company LLC raised its price target for Cytokinetics (NASDAQ:CYTK) from $102 to $112, maintaining a "buy" rating and indicating a potential upside of 41.92%. This positive outlook is supported by a "Moderate Buy" consensus from analysts, with the company also exceeding quarterly earnings and revenue expectations despite a year-over-year revenue decline. Several other firms have also issued positive ratings and price targets for the biopharmaceutical company.
How Investors May Respond To Cytokinetics (CYTK) UK MYQORZO Approval Amid Wider Quarterly Loss
Cytokinetics (CYTK) recently reported a wider net loss in Q2 2026, with revenue decreasing year-over-year. Despite this, the company's cardiac myosin inhibitor, MYQORZO, received UK marketing authorization, offering a potential catalyst for growth. The article discusses how this approval and early MYQORZO uptake could influence Cytokinetics' investment narrative, balancing commercial potential against ongoing financial losses and the need for significant revenue growth.
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics announced its second-quarter 2026 financial results, reporting MYQORZO net product revenue of $25.3 million. The company has significant cash reserves of approximately $1.7 billion and is preparing to submit a supplemental NDA for aficamten in non-obstructive HCM in Q4 2026, following positive Phase 3 trial results. MYQORZO has launched in Germany, received approval in the UK, and is under regulatory review in several other countries, demonstrating strong commercial momentum and pipeline progression.
Cytokinetics (NASDAQ:CYTK) Beats Q2 Estimates on Strong MYQORZO Launch
Cytokinetics (NASDAQ:CYTK) exceeded Q2 2026 estimates, reporting a narrower-than-expected loss and product revenue significantly above forecasts, driven by the successful launch of its cardiac drug MYQORZO. Despite the strong financial performance, the company's shares remained unchanged in after-market trading, suggesting the positive results were largely anticipated. Investors are now looking to the upcoming ACACIA-HCM Phase 3 trial results and the supplemental New Drug Application submission for further market direction.
Cytokinetics Q2 2026 Earnings Call Transcript
Cytokinetics reported strong Q2 2026 earnings, driven by better-than-expected MYQORZO launch momentum, with $25.3 million in net product revenue and increased prescriber adoption. The company also announced positive Phase III trial results for aficamten in non-obstructive HCM, planning a supplemental NDA submission in Q4 2026, and expanded its international presence with launches in Germany and reimbursement approvals in other European countries. Despite a widened net loss, Cytokinetics ended the quarter with $1.7 billion in cash, providing capital for continued commercialization and pipeline advancement.
Earnings Flash (CYTK) Cytokinetics, Incorporated Reports Q2 Revenue $28.6M, vs. FactSet Est of $17.6M
Cytokinetics, Incorporated (CYTK) reported its Q2 revenue at $28.6 million, significantly surpassing FactSet's estimate of $17.6 million. The article also mentions recent insider stock sales and regulatory approvals for its heart disease drugs, MYQORZO (Aficamten) and omecamtiv mecarbil. The company specializes in developing muscle biology-directed drug candidates for cardiovascular diseases.
Cytokinetics Reports Second Quarter 2026 Financial Results and Provides Business Update
Cytokinetics (Nasdaq: CYTK) reported strong second-quarter 2026 financial results, including $25 million in MYQORZO net product revenue and approximately $1.7 billion in cash, cash equivalents, and investments. The company highlighted significant progress in the commercial launch of MYQORZO for obstructive hypertrophic cardiomyopathy (oHCM), with market authorization in the UK and launch in Germany, and announced positive Phase 3 results for aficamten in non-obstructive HCM (nHCM), with plans for a supplemental NDA submission in Q4 2026. Cytokinetics also updated its full-year 2026 financial guidance for R&D and SG&A expenses, reflecting increased investments for the potential 2027 launch of MYQORZO in nHCM.
How Cytokinetics Incorporated (CYTK) Affects Rotational Strategy Timing
The article analyzes Cytokinetics Incorporated (CYTK) using AI models, revealing divergent sentiment across various time horizons and suggesting choppy market conditions. It outlines three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to optimize position sizing and manage risk for different investor profiles. The analysis highlights an exceptional risk-reward short setup for CYTK.
Enterprise value to revenue forward of Cytokinetics, Incorporated – BX:KK3A
This article displays the "Enterprise value to revenue forward" metric for Cytokinetics, Incorporated (BX:KK3A) on TradingView. It provides financial overview, documents, news, and community features related to the company. The page also includes various market data, tools, and community resources offered by TradingView.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Cytokinetics, Incorporated (CYTK) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC has announced an investigation into Cytokinetics, Incorporated (NASDAQ: CYTK) regarding potential corporate wrongdoing. The firm is encouraging shareholders who purchased Cytokinetics securities before December 27, 2023, and still hold them, to contact them to assist with the investigation. Bronstein, Gewirtz & Grossman, LLC represents investors in class actions on a contingency fee basis.
CYTK|Cytokinetics Inc|Price:78.690|Chg%:+2.240
Cytokinetics Inc (CYTK) exhibits weak fundamentals but high growth potential, with its valuation considered fairly priced within the Biotechnology & Medical Research industry. Institutional ownership is very high, and analysts have consistently rated it as a "Buy" with a target price of $108.47. Despite recent market performance, the company shows strong underlying fundamentals and is in a growing phase with significant revenue and profit increases.
Analysts Offer Insights on Healthcare Companies: Labcorp Holdings (LH) and Cytokinetics (CYTK)
This article highlights bullish analyst sentiments for two healthcare companies: Labcorp Holdings (LH) and Cytokinetics (CYTK). William Blair analyst Jared Haase maintained a Buy rating on Labcorp Holdings with a $313.43 average price target, while H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on Cytokinetics with a $140.00 price target. Both companies received a "Strong Buy" consensus rating from analysts, indicating positive outlooks for their respective stocks.
Enterprise value to EBITDA forward of Cytokinetics, Incorporated – NASDAQ:CYTK
This article provides an overview of the "Enterprise value to EBITDA forward" metric for Cytokinetics, Incorporated (NASDAQ: CYTK) as listed on TradingView. It indicates that the data is sourced from ICE Data Services and FactSet, with SEC filings from Quartr. The content mainly consists of navigational elements and disclaimers, with the actual financial value being absent.
The Bull Case For Cytokinetics (CYTK) Could Change Following UK NHS Backing Of Aficamten Access
Cytokinetics recently received marketing authorization in the UK for MYQORZO (aficamten) for obstructive hypertrophic cardiomyopathy, with NICE recommending its use within the NHS. This development strengthens the investment thesis for Cytokinetics by expanding access for its key drug, though the company still faces financial risks related to R&D funding and the speed of aficamten's global adoption. The approval could potentially shift analyst revenue and earnings projections for the company.
Cytokinetics (CYTK) insider schedules 24,000-share option-related stock sale
Cytokinetics insider Andrew Callos has filed a Form 144 to sell 24,000 shares of common stock on July 30, 2026, connected to an exercise of stock options. The filing also details previous Rule 10b5-1 plan sales by Callos in May and June 2026, outlining the number of shares and proceeds from each transaction. This indicates planned insider trading activity and provides transparency into Callos's stock movements.
Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales
Cytokinetics announced that the MHRA has granted marketing authorization for MYQORZO® (aficamten) in the United Kingdom for treating symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. Concurrently, the National Institute for Health and Care Excellence (NICE) issued positive guidance recommending aficamten for use in England and Wales. This decision is based on data from the SEQUOIA-HCM study, showing significant improvement in peak oxygen uptake.
The Bull Case For Cytokinetics (CYTK) Could Change Following UK NHS Backing Of Aficamten Access
Cytokinetics recently secured marketing authorization for MYQORZO (aficamten) in the UK to treat obstructive hypertrophic cardiomyopathy, with NICE recommending its use within the NHS. This approval, supported by Phase 3 trial data, is a significant step for the company, reinforcing its investment narrative around aficamten becoming a globally reimbursed therapy. However, the article also notes that while this backing is positive, Cytokinetics still faces execution risks related to broader launches, reimbursement hurdles, and continued reliance on capital markets for funding its substantial R&D and launch investments.
Andrew Callos of Cytokinetics Inc (CYTK) sells 14,000 shares after exercising options
Andrew Callos, EVP and Chief Commercial Officer of Cytokinetics Inc (CYTK), exercised 14,000 non-qualified stock options at $23.26 per share and subsequently sold all 14,000 shares at $79.88 per share under a Rule 10b5-1 trading plan. After these transactions, he holds 10,000 stock options and 58,555 shares of common stock. The options have a four-year vesting schedule, with 25% vesting after one year and the remainder monthly over 36 months, contingent on continued employment.
Cytokinetics wins UK approval, NICE backing for heart disease drug
Cytokinetics' drug Myqorzo for obstructive hypertrophic cardiomyopathy (oHCM) has received approval from Britain's medicines regulator and a recommendation for NHS reimbursement from the National Institute for Health and Care Excellence (NICE). This will make the drug accessible to an estimated 6,600 patients in England and Wales, expanding its market beyond the U.S. where it was approved in December 2025. Myqorzo is a cardiac myosin inhibitor, similar to Bristol Myers Squibb's Camzyos.
Cytokinetics' cardiomyopathy drug cleared for NHS use
Cytokinetics' cardiac myosin inhibitor Myqorzo has received clearance for NHS use in the UK, making it a competitor to Bristol Myers Squibb's Camzyos. The drug is approved as an add-on treatment for adults with NYHA class II-III obstructive hypertrophic cardiomyopathy (HCM). This approval follows a unique dual regulatory and reimbursement appraisal by the MHRA and NICE, and Cytokinetics anticipates blockbuster sales, especially given Myqorzo's efficacy in non-obstructive HCM.
